Purpose of Review: We provide a state of the art of therapeutic options in hypertrophic cardiomyopathy (HCM), focusing on recent advances in our understanding of the pathophysiology of sarcomeric disease. Recent Findings: A wealth of novel information regarding the molecular mechanisms associated with the clinical phenotype and natural history of HCM have been developed over the last two decades. Such advances have only recently led to a number of controlled randomized studies, often limited in size and fortune. Recently, however, the allosteric inhibitors of cardiac myosin adenosine triphosphatase, countering the main pathophysiological abnormality associated with HCM-causing mutations, i.e. hypercontractility, have opened new management perspectives. Mavacamten is the first drug specifically developed for HCM used in a successful phase 3 trial, with the promise to reach symptomatic obstructive patients in the near future. In addition, the fine characterization of cardiomyocyte electrophysiological remodelling has recently highlighted relevant therapeutic targets. Summary: Current therapies for HCM focus on late disease manifestations without addressing the intrinsic pathological mechanisms. However, novel evidence-based approaches have opened the way for agents targeting HCM molecular substrates. The impact of these targeted interventions will hopefully alter the natural history of the disease in the near future.

Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives / Zampieri M.; Berteotti M.; Ferrantini C.; Tassetti L.; Gabriele M.; Tomberli B.; Castelli G.; Cappelli F.; Stefano P.; Marchionni N.; Coppini R.; Olivotto I.. - In: CURRENT HEART FAILURE REPORTS. - ISSN 1546-9530. - ELETTRONICO. - (2021), pp. 1095-1103. [10.1007/s11897-021-00523-0]

Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives

Zampieri M.
;
Berteotti M.;Ferrantini C.;Tassetti L.;Tomberli B.;Cappelli F.;Stefano P.;Marchionni N.;Coppini R.;Olivotto I.
2021

Abstract

Purpose of Review: We provide a state of the art of therapeutic options in hypertrophic cardiomyopathy (HCM), focusing on recent advances in our understanding of the pathophysiology of sarcomeric disease. Recent Findings: A wealth of novel information regarding the molecular mechanisms associated with the clinical phenotype and natural history of HCM have been developed over the last two decades. Such advances have only recently led to a number of controlled randomized studies, often limited in size and fortune. Recently, however, the allosteric inhibitors of cardiac myosin adenosine triphosphatase, countering the main pathophysiological abnormality associated with HCM-causing mutations, i.e. hypercontractility, have opened new management perspectives. Mavacamten is the first drug specifically developed for HCM used in a successful phase 3 trial, with the promise to reach symptomatic obstructive patients in the near future. In addition, the fine characterization of cardiomyocyte electrophysiological remodelling has recently highlighted relevant therapeutic targets. Summary: Current therapies for HCM focus on late disease manifestations without addressing the intrinsic pathological mechanisms. However, novel evidence-based approaches have opened the way for agents targeting HCM molecular substrates. The impact of these targeted interventions will hopefully alter the natural history of the disease in the near future.
2021
1095
1103
Goal 3: Good health and well-being for people
Zampieri M.; Berteotti M.; Ferrantini C.; Tassetti L.; Gabriele M.; Tomberli B.; Castelli G.; Cappelli F.; Stefano P.; Marchionni N.; Coppini R.; Olivotto I.
File in questo prodotto:
File Dimensione Formato  
Zampieri2021_Article_PathophysiologyAndTreatmentOfH.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1239336
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
social impact